Skip to main content
Erschienen in: Journal of Diabetes & Metabolic Disorders 2/2019

11.09.2019 | Research article

The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver

verfasst von: Mohammad Rashidmayvan, Majid Mohammadshahi, Seyed Saeed Seyedian, Mohammad Hossein Haghighizadeh

Erschienen in: Journal of Diabetes & Metabolic Disorders | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is one of the metabolic disturbances associated with inflammation. Nigella sativa (NS) seed oil has different chemical compounds including Thymoquinone (TQ), unsaturated fatty acids, and flavonoids. NSs are used as anti-inflammatory and antioxidants in medical sciences. This study aimed to investigate the effect of NS oil on several parameters in serum levels of patients with NAFLD.

Methods

Forty-four patients diagnosed with NAFLD participated in a randomized, double-blind, placebo-controlled clinical trial. Patients were randomly assigned into two groups; one receiving NS oil and the other receiving placebo (paraffin oil), for 8 weeks. Blood samples were taken from the patients at the beginning and the end of the study. Afterwards, liver enzymes (ALT, AST, and GGT), inflammatory markers (Hs-CRP, TNF-α, and IL-6), insulin, lipid profiles (total cholesterol, triglyceride, VLDL, LDL-C, and HDL-C), FBS, and blood pressure were measured.

Results

Consumption of NS seed oil as supplement decreased the FBS level, lipid profiles (TG, TC, LDL, VLDL), liver enzymes (AST and ALT), hs-CRP inflammatory marker, IL-6, TNF-α, while it increased the HDL-C levels, compared to the placebo group (P < 0.05). Receiving NS oil had no significant effect on serum levels of insulin, blood pressure, and GGT in comparison with the beginning of the study (P < 0.05).

Conclusion

NS seed oil supplements may decrease the liver enzymes and lipid profiles in the patients with NAFLD and play a protective role in the liver via reducing the inflammation in this group of patients.
Literatur
2.
3.
Zurück zum Zitat Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes mellitus predicts occurrence of cirrhosis an hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases. J Clin Transl Hepatol. 2015;3:9–16.PubMedPubMedCentralCrossRef Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes mellitus predicts occurrence of cirrhosis an hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases. J Clin Transl Hepatol. 2015;3:9–16.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.PubMedCrossRef Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.PubMedCrossRef
5.
Zurück zum Zitat Rinella M, Charlton M. The globalization of non-alcoholic fatty liver disease-prevalence and impact on world health. Hepatology (Baltimore, Md). 2016;64:19–22.CrossRef Rinella M, Charlton M. The globalization of non-alcoholic fatty liver disease-prevalence and impact on world health. Hepatology (Baltimore, Md). 2016;64:19–22.CrossRef
6.
Zurück zum Zitat Khoshbaten M. Comparison character of clinical and laboratory of nonalcoholic fatty liver disease with healthy people. J Tabib Shargh Sci; 2009. P: 13-21.] Persian. Khoshbaten M. Comparison character of clinical and laboratory of nonalcoholic fatty liver disease with healthy people. J Tabib Shargh Sci; 2009. P: 13-21.] Persian.
7.
Zurück zum Zitat Jou J, Choi SS, Diehl AM, editors. Mechanisms of disease progression in nonalcoholic fatty liver disease2008. Jou J, Choi SS, Diehl AM, editors. Mechanisms of disease progression in nonalcoholic fatty liver disease2008.
8.
Zurück zum Zitat Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):8425.CrossRef Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):8425.CrossRef
10.
Zurück zum Zitat Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–42.PubMedCrossRef Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–42.PubMedCrossRef
12.
Zurück zum Zitat Hawsawi ZA, Ali BA, Bamosa AO. Effect of Nigella sativa (black seed) and thymoquinone on blood glucose in albino rats. Ann Saudi Med. 2001;21(3–4):242–4.PubMedCrossRef Hawsawi ZA, Ali BA, Bamosa AO. Effect of Nigella sativa (black seed) and thymoquinone on blood glucose in albino rats. Ann Saudi Med. 2001;21(3–4):242–4.PubMedCrossRef
13.
Zurück zum Zitat Akram KM. Chemical composition and medicinal properties of Nigella sativa Linn. Inflammopharmacol. 1999;7:15–35.CrossRef Akram KM. Chemical composition and medicinal properties of Nigella sativa Linn. Inflammopharmacol. 1999;7:15–35.CrossRef
14.
Zurück zum Zitat Burits M, Bucar F. Antioxidant activity of Nigella sativa essential oil. Phytother Res. 2000;14:323–8.PubMedCrossRef Burits M, Bucar F. Antioxidant activity of Nigella sativa essential oil. Phytother Res. 2000;14:323–8.PubMedCrossRef
15.
Zurück zum Zitat Hajhashemi V, Ghannadi A, Jafarabadi H. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phytother Res. 2004;18(3):195–9.PubMedCrossRef Hajhashemi V, Ghannadi A, Jafarabadi H. Black cumin seed essential oil, as a potent analgesic and antiinflammatory drug. Phytother Res. 2004;18(3):195–9.PubMedCrossRef
16.
Zurück zum Zitat Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed. 2013;3(5):337–52.PubMedPubMedCentralCrossRef Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed. 2013;3(5):337–52.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Mansour MA, Ginawi OT, El-Hadiyah T, El-Khatib AS, Al-Shabanah OA, Al-Sawaf HA. Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. Res Commun Mol Pathol Pharmacol. 2001;110(3–4):239–51.PubMed Mansour MA, Ginawi OT, El-Hadiyah T, El-Khatib AS, Al-Shabanah OA, Al-Sawaf HA. Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. Res Commun Mol Pathol Pharmacol. 2001;110(3–4):239–51.PubMed
18.
Zurück zum Zitat Soliman MM, Baiomy AA, Yassin MH. Molecular and histopathological study on the ameliorative effects of curcumin against lead acetate-induced hepatotoxicity and nephrototoxicity in wistar rats. Biol Trace Elem Res. 2015;167:91–102.PubMedCrossRef Soliman MM, Baiomy AA, Yassin MH. Molecular and histopathological study on the ameliorative effects of curcumin against lead acetate-induced hepatotoxicity and nephrototoxicity in wistar rats. Biol Trace Elem Res. 2015;167:91–102.PubMedCrossRef
19.
Zurück zum Zitat Zaoui A, Cherrah Y, Mahassini N, Alaoui K, Amarouch H, Hassar M. Acute and chronic toxicity of Nigella sativa fixed oil. Phytomedicine. 2002;9(1):69–74.PubMedCrossRef Zaoui A, Cherrah Y, Mahassini N, Alaoui K, Amarouch H, Hassar M. Acute and chronic toxicity of Nigella sativa fixed oil. Phytomedicine. 2002;9(1):69–74.PubMedCrossRef
20.
Zurück zum Zitat Hussain M, Tunio AG, Arain LA, Shaikh GS. Effects of nigella sativa on various parameters in patients of non-alcoholic fatty liver disease. J Ayub Med Coll Abbottabad. 2017;29(3):403–7.PubMed Hussain M, Tunio AG, Arain LA, Shaikh GS. Effects of nigella sativa on various parameters in patients of non-alcoholic fatty liver disease. J Ayub Med Coll Abbottabad. 2017;29(3):403–7.PubMed
21.
Zurück zum Zitat Najmi A, Haque SF, Naseeruddin M, Khan RA. Effect of Nigella sativa oil on various clinical and biochemical parameters of metabolic syndrome. Int J Diabetes Dev Ctries. 2008;16:85–7. Najmi A, Haque SF, Naseeruddin M, Khan RA. Effect of Nigella sativa oil on various clinical and biochemical parameters of metabolic syndrome. Int J Diabetes Dev Ctries. 2008;16:85–7.
22.
Zurück zum Zitat Sabzghabaee AM, Dianatkhah M, Sarrafzadegan N, Asgary S, Ghannadi A. Clinical evaluation of Nigella sativa seeds for the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial. Med Arch. 2012;66(3):198.PubMedCrossRef Sabzghabaee AM, Dianatkhah M, Sarrafzadegan N, Asgary S, Ghannadi A. Clinical evaluation of Nigella sativa seeds for the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial. Med Arch. 2012;66(3):198.PubMedCrossRef
23.
Zurück zum Zitat Mahdavi R, Alizadeh M, Namazi N, Farajnia S. Changes of body composition and circulating adipokines in response to Nigella sativa oil with a calorie restricted diet in obese women. J Herb Med. 2016;6(2):67–72.CrossRef Mahdavi R, Alizadeh M, Namazi N, Farajnia S. Changes of body composition and circulating adipokines in response to Nigella sativa oil with a calorie restricted diet in obese women. J Herb Med. 2016;6(2):67–72.CrossRef
24.
Zurück zum Zitat Al-Naqeep G, Ismail M, Allaudin Z. Regulation of low-density lipoproteinreceptor and 3-hydroxy-3- methylglutaryl coenzyme a reductase geneexpression by thymoquinone-rich fraction and thymoquinone in HepG2cells. J Nutrigenet Nutrigenomics. 2010;2(4–5):163–72. Al-Naqeep G, Ismail M, Allaudin Z. Regulation of low-density lipoproteinreceptor and 3-hydroxy-3- methylglutaryl coenzyme a reductase geneexpression by thymoquinone-rich fraction and thymoquinone in HepG2cells. J Nutrigenet Nutrigenomics. 2010;2(4–5):163–72.
25.
Zurück zum Zitat Al-Naqeeb G, Ismail M. Regulation of apolipoprotein A-1 andapolipoprotein B100 genes by thymoquinone rich fraction andthymoquinone in HEPG2 cells. J Food Lipids. 2009;16(2):245–58.CrossRef Al-Naqeeb G, Ismail M. Regulation of apolipoprotein A-1 andapolipoprotein B100 genes by thymoquinone rich fraction andthymoquinone in HEPG2 cells. J Food Lipids. 2009;16(2):245–58.CrossRef
26.
Zurück zum Zitat Moghadasian MH, Frohlich JJ. Effects of dietary phytosterols oncholesterol metabolism and atherosclerosis: clinical and experimentalevidence. Am J Med. 1999;107(6):588–94.PubMedCrossRef Moghadasian MH, Frohlich JJ. Effects of dietary phytosterols oncholesterol metabolism and atherosclerosis: clinical and experimentalevidence. Am J Med. 1999;107(6):588–94.PubMedCrossRef
27.
Zurück zum Zitat Atta MB. Some characteristics of nigella (Nigella sativa L.) seed cultivated inEgypt and its lipid profile. Food Chem. 2003;83(1):63–8.CrossRef Atta MB. Some characteristics of nigella (Nigella sativa L.) seed cultivated inEgypt and its lipid profile. Food Chem. 2003;83(1):63–8.CrossRef
28.
Zurück zum Zitat Bamosa AO, Ali BA, Sowayan SA. Effect of oral ingestion of Nigella sativaseeds on some blood parameters. Saudi Pharm J. 1997;5(2–3):126–9. Bamosa AO, Ali BA, Sowayan SA. Effect of oral ingestion of Nigella sativaseeds on some blood parameters. Saudi Pharm J. 1997;5(2–3):126–9.
29.
Zurück zum Zitat Mahdavi R, Namazi N, Alizadeh M, Farajnia S. Effects of Nigella sativa oilwith a low-calorie diet on cardiometabolic risk factors in obese women: arandomized controlled clinical trial. Food Funct. 2015;6(6):2041–8.PubMedCrossRef Mahdavi R, Namazi N, Alizadeh M, Farajnia S. Effects of Nigella sativa oilwith a low-calorie diet on cardiometabolic risk factors in obese women: arandomized controlled clinical trial. Food Funct. 2015;6(6):2041–8.PubMedCrossRef
30.
Zurück zum Zitat Woo C, Kumar A, Sethi G, Tan K. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83:443–51.PubMedCrossRef Woo C, Kumar A, Sethi G, Tan K. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83:443–51.PubMedCrossRef
31.
Zurück zum Zitat Umar S, Zargan J, Ahmad S, Katiyar C, Khan H. Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. Chem Biol Interact. 2012;197:40–6.PubMedCrossRef Umar S, Zargan J, Ahmad S, Katiyar C, Khan H. Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. Chem Biol Interact. 2012;197:40–6.PubMedCrossRef
32.
Zurück zum Zitat Sankaranarayanan C, Pari L. Thymoquinone ameliorates chemical induced oxidative stress and b-cell damage in experimental hyperglycemic rats. Chem Biol Interact. 2011;190:148–54.PubMedCrossRef Sankaranarayanan C, Pari L. Thymoquinone ameliorates chemical induced oxidative stress and b-cell damage in experimental hyperglycemic rats. Chem Biol Interact. 2011;190:148–54.PubMedCrossRef
33.
Zurück zum Zitat Evirgen O, Go¨kc¸e A, Ozturk O, Nacar E, et al. Effect of thymoquinone on oxidative stress in Escherichia coli-induced pyelonephritis in rats. Curr Ther Res. 2011;72:204–15.PubMedCrossRef Evirgen O, Go¨kc¸e A, Ozturk O, Nacar E, et al. Effect of thymoquinone on oxidative stress in Escherichia coli-induced pyelonephritis in rats. Curr Ther Res. 2011;72:204–15.PubMedCrossRef
34.
Zurück zum Zitat Ammar E, Gameil N, Shawky N, Nader M. Comparative evaluation of anti-inflammatory properties of thymoquinone and curcumin using an asthmatic murine model. Int Immunopharmacol. 2011;11:2232–6.CrossRef Ammar E, Gameil N, Shawky N, Nader M. Comparative evaluation of anti-inflammatory properties of thymoquinone and curcumin using an asthmatic murine model. Int Immunopharmacol. 2011;11:2232–6.CrossRef
35.
Zurück zum Zitat Marsik P, Kokoska L, Landa P, Nepovim A, Soudek P, Vanek T. In vitro inhibitory effects of thymol and quinones of Nigella sativa seed on cyclooxigenase-1- and −2-catalyzed prostaglandin E2 biosyntheses. Planta Med. 2005;71:739–42.PubMedCrossRef Marsik P, Kokoska L, Landa P, Nepovim A, Soudek P, Vanek T. In vitro inhibitory effects of thymol and quinones of Nigella sativa seed on cyclooxigenase-1- and −2-catalyzed prostaglandin E2 biosyntheses. Planta Med. 2005;71:739–42.PubMedCrossRef
36.
Zurück zum Zitat El-Dakhakhny M, Madi J, Lembert N, Ammon P. Nigella sativa oil, nigellone and derived thymoquinone inhibit synthesis of 5-lipoxygenase products in polymorphonuclear leukocytes from rats. J Ethnopharmacol. 2002;81:161–4.PubMedCrossRef El-Dakhakhny M, Madi J, Lembert N, Ammon P. Nigella sativa oil, nigellone and derived thymoquinone inhibit synthesis of 5-lipoxygenase products in polymorphonuclear leukocytes from rats. J Ethnopharmacol. 2002;81:161–4.PubMedCrossRef
37.
Zurück zum Zitat Nagi N, Mansour A. Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res. 2000;41:283–9.PubMedCrossRef Nagi N, Mansour A. Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res. 2000;41:283–9.PubMedCrossRef
38.
Zurück zum Zitat Heshmati J, Namazi N, Memarzadeh MR, Taghizadeh M, Kolahdooz F. Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Food Res Int. 2015;70:87–93.CrossRef Heshmati J, Namazi N, Memarzadeh MR, Taghizadeh M, Kolahdooz F. Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Food Res Int. 2015;70:87–93.CrossRef
39.
Zurück zum Zitat Bamosa AO, Kaatabi H, Lebdaa FM, Elq AM, Al-Sultanb A. Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian J Physiol Pharmacol. 2010;54(4):344–54.PubMed Bamosa AO, Kaatabi H, Lebdaa FM, Elq AM, Al-Sultanb A. Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian J Physiol Pharmacol. 2010;54(4):344–54.PubMed
40.
Zurück zum Zitat Benhaddou-Andaloussi A, Martineau L, Vuong T, Meddah B, Madiraju P, Settaf A, et al. The in vivo antidiabetic activity of Nigella sativa is mediated through activation of the AMPK pathway and increased muscle Glut4 content. Evid Based Complement Alternat Med. 2011;2011:1–9.CrossRef Benhaddou-Andaloussi A, Martineau L, Vuong T, Meddah B, Madiraju P, Settaf A, et al. The in vivo antidiabetic activity of Nigella sativa is mediated through activation of the AMPK pathway and increased muscle Glut4 content. Evid Based Complement Alternat Med. 2011;2011:1–9.CrossRef
41.
Zurück zum Zitat Awad AS, Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389(4):381–91.CrossRef Awad AS, Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389(4):381–91.CrossRef
42.
Zurück zum Zitat Al okby SY, Mohamed DA, Hamed TE, Edris AE. Potential protective effect of Nigella sativa crude oils towards fatty liver in rats. Eur J Lipid Sci Technol. 2013;115(7):774–82.CrossRef Al okby SY, Mohamed DA, Hamed TE, Edris AE. Potential protective effect of Nigella sativa crude oils towards fatty liver in rats. Eur J Lipid Sci Technol. 2013;115(7):774–82.CrossRef
Metadaten
Titel
The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver
verfasst von
Mohammad Rashidmayvan
Majid Mohammadshahi
Seyed Saeed Seyedian
Mohammad Hossein Haghighizadeh
Publikationsdatum
11.09.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Diabetes & Metabolic Disorders / Ausgabe 2/2019
Elektronische ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00439-6

Weitere Artikel der Ausgabe 2/2019

Journal of Diabetes & Metabolic Disorders 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.